Genetic variants in CCL5 and CCR5 genes and serum VEGF-A levels predict efficacy of bevacizumab in metastatic colorectal cancer patients

Early VEGF-A reduction (EVR) by targeting abundant VEGF-A is a potential predictive marker of bevacizumab (BEV). The CCL5/ CCR5 axis modulates VEGF-A production via endothelial progenitor cells migration. We tested whether genetic polymorphisms in the CCL5/CCR5 pathway could predict efficacy of BEV...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Int J Cancer
Autori principali: Suenaga, Mitsukuni, Cao, Shu, Zhang, Wu, Yang, Dongyun, Ning, Yan, Okazaki, Satoshi, Berger, Martin D., Miyamoto, Yuji, Schirripa, Marta, Soni, Shivani, Barzi, Afsaneh, Yamaguchi, Toshiharu, Lenz, Heinz-Josef
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2018
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7497849/
https://ncbi.nlm.nih.gov/pubmed/30411783
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ijc.31968
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi